WA

Written & reviewed by WhatAreAllergies Editorial Team

Editorial Review

Health Editors & Medical Writers · Allergy, Immunology & Clinical Health Content

WhatAreAllergies.com

Updated May 2026·Annual review cycle

Our editorial process: All content on WhatAreAllergies.com is written and reviewed by our editorial team following published guidelines from ACAAI, AAAAI, WAO, and ARIA. Content is updated annually or when major guidelines change. This content is educational only — not a substitute for professional medical advice. We do not accept advertising influence on editorial content. Read our editorial policy →

Quick Answer

Peanut allergy is the most common cause of food-related anaphylaxis and affects approximately 1.2–2% of the US population. It is caused by IgE antibodies to peanut proteins, especially Ara h 2. Symptoms range from skin hives to life-threatening anaphylaxis. Treatment includes strict avoidance, epinephrine auto-injectors, and optionally oral immunotherapy.

Peanut Allergens: What the Immune System Reacts To

Peanuts contain at least 17 identified allergen proteins, designated Ara h 1 through Ara h 17. The most clinically significant are Ara h 2 (a 2S albumin), which is the strongest predictor of systemic reactions and is detected in patients at highest risk for anaphylaxis; Ara h 1 and Ara h 3, which cause a range of reaction severities; and Ara h 8, a PR-10 protein that cross-reacts with birch pollen and typically causes only oral allergy syndrome.

Component-resolved diagnostics can test for specific Ara h proteins, allowing allergists to stratify reaction risk. High Ara h 2 sensitivity strongly predicts systemic anaphylaxis risk, while isolated Ara h 8 sensitivity typically indicates pollen-food allergy syndrome with only mild oral symptoms rather than systemic allergy.

Symptoms of Peanut Allergy

Peanut allergy symptoms span the full spectrum of IgE-mediated reactions: mild oral tingling or hives; moderate urticaria, vomiting, and rhinitis; and severe anaphylaxis with throat closure, bronchospasm, and cardiovascular collapse. Peanut allergy is responsible for approximately 150–200 food allergy deaths annually in the United States, making reaction severity recognition critical.

Reactions typically begin within 5–30 minutes of peanut ingestion. In highly sensitized individuals, even trace exposures from shared equipment, kissing a peanut-consumer, or airborne roasting peanut exposure can potentially trigger symptoms, though airborne reactions are considerably less common than ingestion reactions.

Early Peanut Introduction: The LEAP Trial

The landmark LEAP (Learning Early About Peanut Allergy) trial, published in 2015, demonstrated that introducing peanut products to high-risk infants (those with severe eczema or egg allergy) between 4 and 11 months of age reduced peanut allergy development by 80% compared to avoidance. This finding reversed 15 years of medical guidance advising delayed introduction.

Current NIAID guidelines (2017) recommend early peanut introduction at 4–6 months for high-risk infants, with allergist evaluation (and potentially supervised introduction) for those with severe eczema or established egg allergy, and routine early introduction for moderate- and low-risk infants. Age-appropriate peanut-containing foods (smooth peanut butter thinned with water, peanut puffs) are recommended from around 6 months.

Treatment: Avoidance, Epinephrine, and Oral Immunotherapy

Strict peanut avoidance remains the cornerstone of peanut allergy management. This includes reading all food labels (peanuts must be declared under FALCPA), alerting restaurants, carrying two epinephrine auto-injectors at all times, wearing medical identification, and having a written emergency action plan reviewed by an allergist.

Palforzia (AR101), the first FDA-approved peanut OIT product, is indicated for desensitization in patients ages 4–17. Treatment uses a structured up-dosing protocol over approximately 6 months to achieve a maintenance dose of 300mg peanut protein daily. Palforzia reduces the risk of severe reactions from accidental ingestion but does not eliminate peanut allergy and requires ongoing daily maintenance dosing.

Key Takeaways

  • Peanut allergy affects 1.2–2% of Americans and is the leading cause of food allergy fatality.
  • Ara h 2 is the most important peanut allergen component predicting systemic reaction risk.
  • LEAP trial: early peanut introduction at 4–11 months reduces peanut allergy by 80% in high-risk infants.
  • Every peanut-allergic patient needs two epinephrine auto-injectors and a written emergency action plan.
  • Palforzia OIT can desensitize peanut-allergic patients but requires lifelong maintenance dosing.

Frequently Asked Questions

Is peanut a nut?
No. Despite the name, peanuts are legumes (related to soybeans and lentils), not tree nuts. Peanuts grow underground as the seed of the Arachis hypogaea plant. Approximately 25–40% of peanut-allergic patients are also allergic to one or more tree nuts, but the allergies have distinct mechanisms and cross-reactivity is not universal.
Can peanut allergy develop in adulthood?
Yes. While peanut allergy most often first appears in early childhood, adult-onset peanut allergy is documented. Adults who develop peanut allergy typically have more severe initial reactions than children who develop it gradually. Any new reaction to peanut in an adult warrants allergist evaluation and likely prescription of epinephrine auto-injectors.
Are peanut-free schools effective at preventing reactions?
Research shows that peanut bans in schools have limited effectiveness as a sole intervention because peanut can enter school environments in many ways and cross-contact is difficult to eliminate. An individual allergy management plan combining staff training, epinephrine access, and 504 accommodations is more evidence-based than school-wide bans as the primary safety strategy.

About the Medical Team

WA
Medical Review

WhatAreAllergies Editorial Team,

Health Editors & Medical Writers

Allergy, Immunology & Clinical Health Content

WhatAreAllergies.com
WA
Written by

WhatAreAllergies Editorial Team,

Health Content Editor

Clinical Allergy & Immunology Content

WhatAreAllergies.com

Content is written by our editorial team following current clinical guidelines from ACAAI, AAAAI, and WAO. Educational only — always consult a qualified healthcare provider for medical advice. View editorial policy →

Medical References & Citations

  1. 1
    guideline2006

    Sampson HA, et al. "Second symposium on the definition and management of anaphylaxis: Summary report" — Journal of Allergy and Clinical Immunology.

    View source
  2. 2
    database2025

    American College of Allergy, Asthma & Immunology (ACAAI) "Allergy Facts and Figures" — ACAAI Clinical Resources.

    View source
  3. 3
    review2025

    World Allergy Organization (WAO) "White Book on Allergy — 2025 Update" — World Allergy Organization.

    View source
  4. 4
    guideline2024

    National Institute of Allergy and Infectious Diseases (NIAID) "Clinical Guidelines for the Diagnosis and Management of Food Allergy" — National Institutes of Health.

    View source
  5. 5
    guideline2024

    Muraro A, et al. "EAACI food allergy and anaphylaxis guidelines: Diagnosis and management of food allergy" — Allergy — European Journal of Allergy and Clinical Immunology.

This content reflects clinical guidelines current as of the last review date shown above. Always consult a qualified healthcare provider for personalized medical advice.